Endoluminal Sphincter Augmentation with the MUSE™ System and GERDX™ System in the Treatment of Gastroesophageal Reflux Disease: A New Impact?
He S., Feussner H., Nennstiel S., Bajbouj M., Hüser N., Wilhelm D.
1. The Fourth Department of the Digestive Disease Center, Suining Central Hospital, Sichuan, China.
2. Chirurgische Klinik, Klinikum rechts der Isar, Technische Universität München, Germany, Munich, Germany.
3. Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
To bridge the gap between the long-term intake of proton pump inhibitors (PPIs) and the potential risks of laparoscopic fundoplication, a number of endoscopic procedures for the treatment of gastro-esophageal reflux disease (GERD) have been developed over the past 30 years. Because of the minimally invasive approach, short operative time, and efficacy in selected patients, endoluminal sphincter augmentation appears to be highly attractive. However, most early devices have proven to be unsafe or failed to provide long-term symptom relief. Accordingly, products for endoluminal sphincter augmentation have undergone several modifications to achieve an increased lower esophageal sphincter (LES) baseline pressure to re-establish the LES as an efficacious anti-reflux barrier. This paper reviews and discusses the two latest products for endoluminal sphincter augmentation, the MUSE device (Medigus, Ltd., Omer, Israel) and the GERDX system (G-SURG GmbH, Seeon-Seebruck, Germany). While the currently available literature has proven their effectiveness in principle, long-term results are lacking. Further studies and developments are necessary to determine whether these two new devices will truly impact GERD therapy.